Filtered By:
Cancer: Leukemia

This page shows you your search results in order of date.

Order by Relevance | Date

Total 266 results found since Jan 2013.

Profile of Nagasaki Islands Study (NaIS): A Population-Based Prospective Cohort Study on Multi-disease
In conclusion, the NaIS has been undertaken to reveal the influence of aging and risk factors of noncommunicable diseases and disabilities, with an aim to contribute towards better healthcare in the future.PMID:37517991 | DOI:10.2188/jea.JE20230079
Source: Journal of Epidemiology - July 30, 2023 Category: Epidemiology Authors: Jun Miyata Hirotomo Yamanashi Shin-Ya Kawashiri Sakiko Soutome Kazuhiko Arima Mami Tamai Fumiaki Nonaka Yukiko Honda Masayasu Kitamura Koji Yoshida Yuji Shimizu Naomi Hayashida Shigeru Kawakami Noboru Takamura Takashi Sawase Atsutoshi Yoshimura Yasuhiro N Source Type: research

Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose-response meta-analysis of large prospective studies
Conclusions Inverse non-linear dose–response associations suggest substantial protection against a range of chronic disease outcomes from small increases in non-occupational physical activity in inactive adults. PROSPERO registration number CRD42018095481.
Source: British Journal of Sports Medicine - July 20, 2023 Category: Sports Medicine Authors: Garcia, L., Pearce, M., Abbas, A., Mok, A., Strain, T., Ali, S., Crippa, A., Dempsey, P. C., Golubic, R., Kelly, P., Laird, Y., McNamara, E., Moore, S., de Sa, T. H., Smith, A. D., Wijndaele, K., Woodcock, J., Brage, S. Tags: Open access, BJSM Reviews with MCQs, BJSM Systematic review Source Type: research

Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
CONCLUSIONS: The current CML treatment target is a cure that leads to normal age and gender-adjusted survival with a "normal" quality of life. Cardiovascular disorders are one of the major obstacles to reaching this target in CML patients. The treatment choices for CML patients must include a cardiovascular perspective.PMID:37401285 | DOI:10.26355/eurrev_202306_32786
Source: Pharmacological Reviews - July 4, 2023 Category: Drugs & Pharmacology Authors: U Y Malkan I C Haznedaroglu Source Type: research